Novartis and Amgen expand commercial partnership for AMG 334

Novartis has announced that its global commercialisation agreement with Amgen for the migraine prevention therapy AMG 334 is to be expanded.

Under the revised terms of the deal, Novartis and Amgen will co-commercialise AMG 334 in the US, with Novartis retaining exclusive rights to market the drug in the rest of world, including the addition of commercialisation rights in Canada.

Amgen will retain exclusive commercial rights to the asset in Japan, with both companies to continue participating in the global co-development programme.

Paul Hudson, chief executive officer for Novartis Pharmaceuticals, said: "We look forward to combining capabilities and leveraging our strong heritage in neuroscience in the US and Canada to bring erenumab to more patients in need as fast as we can."

AMG 334 is a fully human monoclonal antibody specifically designed for the prevention of migraine, which functions by targeting and blocking the CGRP receptor. The companies have been jointly developing the compound since 2015.

Data from a phase II study and two phase III studies of AMG 334 have shown that the drug can significantly reduce monthly migraine days versus placebo, while also demonstrating an encouraging safety profile.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.